Author(s): Falcão, G ; Barreira, JV ; Parmanande, A ; Carneiro, C ; Campos Pinheiro, L
Date: 2020
Persistent ID: http://hdl.handle.net/10400.17/4243
Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
Subject(s): Bladder cancer; Biomarkers; Bladder cancer/diagnosis; Liquid biopsies; CHLC URO
Bladder cancer is one of the most common neoplasia in men in the developed countries. Diagnosis and surveillance are made by bladder examination through cystoscopy making this one of the most expensive on cost/patient. After tumor removal, clinical staging is important for prognosis and treatment decision as non-muscle invasive (Ta and T1) and invasive (T2+) are treated in a completely different way. Today no noninvasive method has enough sensitivity to substitute cystoscopy or histological examination for tumor clinical staging. Our aim is to identify and quantify in urine, proteins that can detect and classify bladder tumors. A biomarker study was conducted using urine samples from: individuals with bladder cancer; individuals with other genitourinary disorders and individuals without urological diseases. Several proteins were found to successfully help in the discrimination of the bladder cancer stages Ta, T1 and T2+. Two biomarkerpanels were developed, one capable of detecting bladder cancer presence and other able to distinguish Ta, T1 and T2+. Our results show a significant difference between urinary proteome in patients with different bladder cancer stages. This may allow through liquid biopsies predict patient’s cancer stage. A validation study is on progress to attest this biomarker panel’s accuracy.
